Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ashvind Prabahran, Dr
Peter MacCallum Cancer Centre, Australia
Principal Investigator - Henrique Bittencourt, Dr
St. Justine's Hospital
Principal Investigator - Polina Stepensky, Dr
Hadassah Hebrew University
Principal Investigator - Richard Mitchell, Dr
Kids Cancer Centre Sydney Children's Hospital
Principal Investigator - Tsila Zuckerman, Dr
The Rambam Academic Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Peter Maccallum Cancer Centre
Melbourne, Australia
- Kids Cancer Centre Sydney Children'S Hospital
Randwick, Australia
- Chu Sainte-Justine
Montreal, Quebec, Canada
- the Rambam Academic Hospital
Haifa, Israel
- Hadassah Hebrew University
Jerusalem, Israel
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 May 2021
- Primary completion
- 21 Apr 2022
- Completion
- 21 Apr 2022
- Last update posted
- 28 Dec 2023
- Registered enrollment
- 2
- Registry id
- NCT04731298
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.